EP 3872070 A1 20210901 - COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
Title (en)
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
Title (de)
VERBINDUNGEN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON LEIDEN IN ZUSAMMENHANG MIT DER NLRP-AKTIVITÄT
Title (fr)
COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE NLRP
Publication
Application
Priority
- US 201662324081 P 20160418
- US 201662324071 P 20160418
- EP 17720928 A 20170418
- US 2017028167 W 20170418
Abstract (en)
In one aspect, compounds of Formulae I and II, or pharmaceutically acceptable salts thereof, are featured:or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae I and II can be as defined anywhere herein.
IPC 8 full level
C07D 311/54 (2006.01); A61K 31/64 (2006.01); A61P 1/00 (2006.01); A61P 1/04 (2006.01); A61P 1/06 (2006.01); A61P 1/16 (2006.01); A61P 1/18 (2006.01); A61P 3/00 (2006.01); A61P 9/00 (2006.01); A61P 11/00 (2006.01); A61P 19/00 (2006.01); A61P 35/00 (2006.01); C07D 213/34 (2006.01); C07D 213/71 (2006.01); C07D 263/46 (2006.01); C07D 277/36 (2006.01); C07D 295/096 (2006.01); C07D 307/64 (2006.01); C07D 333/34 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01)
CPC (source: EP US)
A61K 31/41 (2013.01 - US); A61P 1/00 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/16 (2017.12 - EP); A61P 1/18 (2017.12 - EP); A61P 3/00 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 5/14 (2017.12 - EP); A61P 5/40 (2017.12 - EP); A61P 7/06 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/14 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/00 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 19/06 (2017.12 - EP); A61P 19/08 (2017.12 - EP); A61P 19/10 (2017.12 - EP); A61P 21/00 (2017.12 - EP); A61P 21/02 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 27/06 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 35/04 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07C 317/22 (2013.01 - US); C07D 213/34 (2013.01 - EP US); C07D 213/71 (2013.01 - EP US); C07D 263/46 (2013.01 - EP US); C07D 277/36 (2013.01 - EP US); C07D 295/096 (2013.01 - EP US); C07D 307/64 (2013.01 - EP US); C07D 311/54 (2013.01 - EP US); C07D 333/34 (2013.01 - EP US); C07D 405/12 (2013.01 - EP US); C07D 417/12 (2013.01 - EP US); C07C 2603/10 (2017.04 - US)
Citation (applicant)
- WO 0119390 A1 20010322 - PFIZER PROD INC [US], et al
- WO 9832733 A1 19980730 - PFIZER [US], et al
- WO 2016131098 A1 20160825 - UNIV QUEENSLAND [AU], et al
- "Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
- "Pharmaceutical Preformulation and Formulation", 2009, THE PHARMACEUTICAL PRESS AND THE AMERICAN PHARMACEUTICAL ASSOCIATION
- "Handbook of Pharmaceutical Additives", 2007, GOWER PUBLISHING COMPANY
- REMINGTON: "The Science and Practice of Pharmacy", 2012, PHARMACEUTICAL PRESS
- LAMMERS ET AL.: "Effect of Intratumoral Injection on the Biodistribution and the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems", NEOPLASIA, vol. 10, 2006, pages 788 - 795
- FILIPSKI, K.J. ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 13, 2013, pages 776 - 802
- R. LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS
- T. W. GREENERGM. WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY AND SONS
- L. FIESERM. FIESER: "Fieser and Fieser's Reagents for Organic Synthesis", 1994, JOHN WILEY AND SONS
- L. PAQUETTE: "Encyclopedia of Reagents for Organic Synthesis", 1995, JOHN WILEY AND SONS
Citation (search report)
- [XDP] WO 2016131098 A1 20160825 - UNIV QUEENSLAND [AU], et al
- [XD] WO 9832733 A1 19980730 - PFIZER [US], et al
- [X] WO 0119390 A1 20010322 - PFIZER PROD INC [US], et al
- [X] EP 1236468 A1 20020904 - WARNER LAMBERT CO [US]
- [A] DK 200600313 A 20060313 - NOVO NORDISK AS [DK]
- [X] FRANCISZEK SĄCZEWSKI ET AL: "Synthesis of Novel Aryl(heteroaryl)sulfonyl Ureas of Possible Biological Interest", MOLECULES, vol. 15, no. 3, 26 February 2010 (2010-02-26), DE, pages 1113 - 1126, XP055306656, ISSN: 1433-1373, DOI: 10.3390/molecules15031113
- [X] ABOU OUF A A ET AL: "THIOPHENE SULPHONYLUREAS STRUCTURALLY RELATED TO ANTIDIABETIC DRUGS", JOURNAL OF DRUG RESEARCH, DRUG RESEARCH AND CONTROL CENTER, GIZA, EG, vol. 6, no. 2, 1 January 1974 (1974-01-01), pages 123 - 129, XP009011580, ISSN: 0368-1866
- [X] YOUSSEF ET AL: "Synthesis of certain diarylsulfonylureas as antitumor agents", MEDICINAL CHEMISTRY RESEARCH, BIRKHAEUSER, BOSTON, US, vol. 10, no. 6, 1 January 2001 (2001-01-01), pages 404 - 418, XP008020857, ISSN: 1054-2523
- [X] JIA XIN-YU ET AL: "Synthesis of N'-substituted phenyl-2-benzothiazolesulfonylureas derivatives", CHINESE JOURNAL OF MEDICINAL CHEMISTRY, GAI-KAI BIANJIBU, SHENYANG, CN, vol. 23, no. 6, 1 January 2013 (2013-01-01), pages 467 - 472, XP009527719, ISSN: 1005-0108, DOI: 10.14142/J.CNKI.CN21-1313/R.2013.06.002
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2017184623 A1 20171026; AU 2017254522 A1 20181101; AU 2017254522 B2 20210923; AU 2017254523 A1 20181101; AU 2017254523 B2 20210902; EP 3445756 A1 20190227; EP 3445756 B1 20220706; EP 3445757 A1 20190227; EP 3445757 B1 20201125; EP 3872070 A1 20210901; ES 2855732 T3 20210924; ES 2927777 T3 20221110; JP 2019515952 A 20190613; JP 2019518071 A 20190627; JP 7050751 B2 20220408; MA 44729 A 20210512; MA 56008 A 20220406; US 11339136 B2 20220524; US 11597706 B2 20230307; US 11760735 B2 20230919; US 2019119203 A1 20190425; US 2019119224 A1 20190425; US 2023099258 A1 20230330; WO 2017184624 A1 20171026
DOCDB simple family (application)
US 2017028166 W 20170418; AU 2017254522 A 20170418; AU 2017254523 A 20170418; EP 17720928 A 20170418; EP 17722216 A 20170418; EP 20208882 A 20170418; ES 17720928 T 20170418; ES 17722216 T 20170418; JP 2019505346 A 20170418; JP 2019505347 A 20170418; MA 44729 A 20170418; MA 56008 A 20170418; US 2017028167 W 20170418; US 201716094491 A 20170418; US 201716094499 A 20170418; US 202217711205 A 20220401